Pure Global AI
NCT06232772Not yet recruiting

Research on Novel Biomarkers for Early Diagnosis of Parkinson's Disease

Yousheng XiaoClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Parkinson's Disease
Drug/Device/Intervention
α- Synuclein Ultrafine Fluorescence Detection Method
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Yousheng Xiao
Funder
Guangxi Medical University
Location
Nanning, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Jun 01, 2026
Enrollment
600 participants
Primary outcome

Primary Outcome 1（Accuracy and precision）,Primary Outcome 2（Sensitivity and specificity）

Summary

The goal of this observational study is to evaluate the detection ability of α-Synuclein
 Ultrafine Fluorescence Detection Method for body fluids (Such as saliva, urine, cerebrospinal
 fluid, and blood, etc.) and skin in Parkinson's patients.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismPostencephalitic parkinsonism
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06232772
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06232772 through Pure Global AI's free database. This phase not specified trial is sponsored by Yousheng Xiao and is currently Not yet recruiting. The study focuses on Parkinson's Disease. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.